These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 33997033

  • 1. Increased Urinary CD163 Levels in Systemic Vasculitis with Renal Involvement.
    Aierken X, Zhu Q, Wu T, Liu SS, Cao YY, Cai XT, Aihemaiti A, Bi Y, Yang S, Zhang W, Li N.
    Biomed Res Int; 2021; 2021():6637235. PubMed ID: 33997033
    [Abstract] [Full Text] [Related]

  • 2. Urinary and serum soluble CD25 complements urinary soluble CD163 to detect active renal anti-neutrophil cytoplasmic autoantibody-associated vasculitis: a cohort study.
    Dekkema GJ, Abdulahad WH, Bijma T, Moran SM, Ryan L, Little MA, Stegeman CA, Heeringa P, Sanders JF.
    Nephrol Dial Transplant; 2019 Feb 01; 34(2):234-242. PubMed ID: 29506265
    [Abstract] [Full Text] [Related]

  • 3. Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Moran SM, Monach PA, Zgaga L, Cuthbertson D, Carette S, Khalidi NA, Koening CL, Langford CA, McAlear CA, Moreland L, Pagnoux C, Seo P, Specks U, Sreih A, Wyse J, Ytterberg SR, Merkel PA, Little MA, Vasculitis Clinical Research Consortium.
    Nephrol Dial Transplant; 2020 Feb 01; 35(2):283-291. PubMed ID: 30380100
    [Abstract] [Full Text] [Related]

  • 4. Urinary Soluble CD163 in Active Renal Vasculitis.
    O'Reilly VP, Wong L, Kennedy C, Elliot LA, O'Meachair S, Coughlan AM, O'Brien EC, Ryan MM, Sandoval D, Connolly E, Dekkema GJ, Lau J, Abdulahad WH, Sanders JS, Heeringa P, Buckley C, O'Brien C, Finn S, Cohen CD, Lindemeyer MT, Hickey FB, O'Hara PV, Feighery C, Moran SM, Mellotte G, Clarkson MR, Dorman AJ, Murray PT, Little MA.
    J Am Soc Nephrol; 2016 Sep 01; 27(9):2906-16. PubMed ID: 26940094
    [Abstract] [Full Text] [Related]

  • 5. Increased Serum MCP-1 Levels in Systemic Vasculitis Patients with Renal Involvement.
    Liu S, Li N, Zhu Q, Zhu B, Wu T, Wang G, Liu S, Luo Q.
    J Interferon Cytokine Res; 2018 Sep 01; 38(9):406-412. PubMed ID: 30230985
    [Abstract] [Full Text] [Related]

  • 6. Serum levels of the soluble haemoglobin scavenger receptor CD163 in MPO-ANCA-associated renal vasculitis.
    Nagai M, Hirayama K, Ebihara I, Higuchi T, Shimohata H, Kobayashi M.
    Scand J Rheumatol; 2016 Oct 01; 45(5):397-403. PubMed ID: 27094919
    [Abstract] [Full Text] [Related]

  • 7. Urinary Soluble CD163 and Disease Activity in Biopsy-Proven ANCA-Associated Glomerulonephritis.
    Aendekerk JP, Timmermans SAMEG, Busch MH, Potjewijd J, Heeringa P, Damoiseaux JGMC, Reutelingsperger CP, van Paassen P, Limburg Renal Registry.
    Clin J Am Soc Nephrol; 2020 Dec 07; 15(12):1740-1748. PubMed ID: 33203735
    [Abstract] [Full Text] [Related]

  • 8. Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritis.
    Endo N, Tsuboi N, Furuhashi K, Shi Y, Du Q, Abe T, Hori M, Imaizumi T, Kim H, Katsuno T, Ozaki T, Kosugi T, Matsuo S, Maruyama S.
    Nephrol Dial Transplant; 2016 Dec 07; 31(12):2023-2033. PubMed ID: 27242373
    [Abstract] [Full Text] [Related]

  • 9. Urinary Soluble CD163: a Novel Noninvasive Biomarker of Activity for Lupus Nephritis.
    Mejia-Vilet JM, Zhang XL, Cruz C, Cano-Verduzco ML, Shapiro JP, Nagaraja HN, Morales-Buenrostro LE, Rovin BH.
    J Am Soc Nephrol; 2020 Jun 07; 31(6):1335-1347. PubMed ID: 32300067
    [Abstract] [Full Text] [Related]

  • 10. The Clinical Application of Urine Soluble CD163 in ANCA-Associated Vasculitis.
    Moran SM, Scott J, Clarkson MR, Conlon N, Dunne J, Griffin MD, Griffin TP, Groarke E, Holian J, Judge C, Wyse J, McLoughlin K, O'Hara PV, Kretzler M, Little MA, Nephrotic Syndrome Study Network (NEPTUNE).
    J Am Soc Nephrol; 2021 Nov 07; 32(11):2920-2932. PubMed ID: 34518279
    [Abstract] [Full Text] [Related]

  • 11. Urinary Soluble CD163 Levels Predict IgA Nephropathy Remission Status.
    Gong S, Jin S, Li Y, Jiang W, Zhang Z, Shen Z, Wang J, Zhou H, Liu X, Xu X, Ding X, Shi Y, Liu H.
    Front Immunol; 2021 Nov 07; 12():769802. PubMed ID: 35003086
    [Abstract] [Full Text] [Related]

  • 12. Association of serum high mobility group box 1 levels with disease activity and renal involvement in patients with systemic vasculitis.
    Zhu B, Li N, Zhu Q, Wu T, Heizati M, Wang G, Yao X, Luo Q, Liu S, Liu S, Hong J.
    Medicine (Baltimore); 2019 Feb 07; 98(6):e14493. PubMed ID: 30732222
    [Abstract] [Full Text] [Related]

  • 13. Clinical impact of urinary CD11b and CD163 on the renal outcomes of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.
    Yokoe Y, Tsuboi N, Imaizumi T, Kitagawa A, Karasawa M, Ozeki T, Endo N, Sawa Y, Kato S, Katsuno T, Maruyama S, Yamagata K, Usui J, Nagata M, Sada KE, Sugiyama H, Amano K, Arimura Y, Atsumi T, Yuzawa Y, Dobashi H, Takasaki Y, Harigai M, Hasegawa H, Makino H, Matsuo S, Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis and for Intractable Renal Disease.
    Nephrol Dial Transplant; 2021 Jul 23; 36(8):1452-1463. PubMed ID: 32639002
    [Abstract] [Full Text] [Related]

  • 14. Association of Urine sCD163 With Proliferative Lupus Nephritis, Fibrinoid Necrosis, Cellular Crescents and Intrarenal M2 Macrophages.
    Zhang T, Li H, Vanarsa K, Gidley G, Mok CC, Petri M, Saxena R, Mohan C.
    Front Immunol; 2020 Jul 23; 11():671. PubMed ID: 32351512
    [Abstract] [Full Text] [Related]

  • 15. Biomarkers in vasculitis.
    Hatemi G, Esatoglu SN, Yazici Y.
    Curr Opin Rheumatol; 2018 Jan 23; 30(1):30-35. PubMed ID: 28937415
    [Abstract] [Full Text] [Related]

  • 16. Soluble CD163 as a Potential Biomarker in Systemic Sclerosis.
    Frantz C, Pezet S, Avouac J, Allanore Y.
    Dis Markers; 2018 Jan 23; 2018():8509583. PubMed ID: 29805720
    [Abstract] [Full Text] [Related]

  • 17. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.
    Valdivielso JM, Coll B, Martín-Ventura JL, Moreno JA, Egido J, Fernández E, Blanco-Colio LM.
    J Nephrol; 2013 Jan 23; 26(6):1105-13. PubMed ID: 23475462
    [Abstract] [Full Text] [Related]

  • 18. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
    Enomoto Y, Suzuki Y, Hozumi H, Mori K, Kono M, Karayama M, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Suzuki D, Ogawa N, Nakashima R, Mimori T, Iwashita T, Suda T.
    Arthritis Res Ther; 2017 Jan 19; 19(1):9. PubMed ID: 28103926
    [Abstract] [Full Text] [Related]

  • 19. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis.
    Kowal-Bielecka O, Bielecki M, Guiducci S, Trzcinska-Butkiewicz B, Michalska-Jakubus M, Matucci-Cerinic M, Brzosko M, Krasowska D, Chyczewski L, Kowal K.
    Arthritis Res Ther; 2013 Jan 19; 15(3):R69. PubMed ID: 23800379
    [Abstract] [Full Text] [Related]

  • 20. Usefulness of soluble CD163 as a biomarker for macrophage activation syndrome associated with systemic lupus erythematosus.
    Nishino A, Katsumata Y, Kawasumi H, Hirahara S, Kawaguchi Y, Yamanaka H.
    Lupus; 2019 Jul 19; 28(8):986-994. PubMed ID: 31246559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.